Creating Premium Biosimilars and Introducing Biobetters for Superior Results

Besides a whole range of 1^st, 2^nd and 3^rd wave biosimilar antibodies, we have successfully developed cell lines for recombinant proteins, such as Factor VIII, Factor VIIa, Interferon beta 1a, and Follicle-Stimulating Hormone (FSH), including all relevant analytics, and (cell-based) potency assays. These biosimilars are already on the market or in various stages of clinical trials.

With our technology platform, we are uniquely positioned to adjust originator product characteristics (even if originally not CHO cell-based) through the combination of

• Different CHO hosts cells
• Clone selection strategy (best match of desired product quality, productivity and large-scale manufacturability)
• Our upstream process development expertise together with our chemically defined media platform to further adjust glycan-profiles
• Our genetic glycan-adjustment technologies to fine-tune the content of fucose, galactose and sialic acid and to overcome media and process adjustment limitations.

Crucial biochemical analytics, cell-based activity assays, and a robust development process are the pillars of success for our wide range of biosimilar antibodies and recombinant proteins.

• In-depth experience with a broad range of biosimilars
• Technology and media for biosimilar and product feature adjustment
• Improving biologics to create biobetters
• Royalty-free technologies